San Francisco — Invitrogen began 2005 much like it ended 2004 — with another acquisition.

The company on Monday announced an agreement to pay $60 million in cash to acquire South San Francisco, Calif.-based Zymed Laboratories, an early-stage immunoassay reagent company that is projected to bring in revenues of $15 million in 2005, and another $22 million in 2006.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.